This website uses cookies

The University of Liège wishes to use cookies or trackers to store and access your personal data, to perform audience measurement. Some cookies are necessary for the website to function. Cookie policy.

Profil

Nguyen Ngoc-Quynh-Nhu

See author's contact details
Main Referenced Co-authors
Struman, Ingrid  (35)
Martial, Joseph  (34)
Noël, Agnès  (17)
Tabruyn, Sébastien  (15)
Blacher, Silvia  (10)
Main Referenced Keywords
16K hPRL (2); Animals (2); Antiangiogenic (2); Humans (2); 16k-Da PRL (1);
Main Referenced Unit & Research Centers
Giga-Cancer - ULiège (4)
Main Referenced Disciplines
Biochemistry, biophysics & molecular biology (18)
Oncology (15)
Biotechnology (2)
Endocrinology, metabolism & nutrition (1)
Ophthalmology (1)

Publications (total 38)

The most downloaded
493 downloads
Hilfiker-Kleiner, D., Kaminski, K., Podewski, E., Bonda, T., Schaefer, A., Sliwa, K., Forster, O., Quint, A., Landmesser, U., Doerries, C., Luchtefeld, M., Poli, V., Schneider, M. D., Balligand, J. L., Desjardins, F., Ansari, A., Struman, I., Nguyen, N.-Q.-N., Zschemisch, N. H., ... Drexler, H. (09 February 2007). A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell, 128 (3), 589-600. doi:10.1016/j.cell.2006.12.036 https://hdl.handle.net/2268/12225

The most cited

846 citations (OpenAlex)

Hilfiker-Kleiner, D., Kaminski, K., Podewski, E., Bonda, T., Schaefer, A., Sliwa, K., Forster, O., Quint, A., Landmesser, U., Doerries, C., Luchtefeld, M., Poli, V., Schneider, M. D., Balligand, J. L., Desjardins, F., Ansari, A., Struman, I., Nguyen, N.-Q.-N., Zschemisch, N. H., ... Drexler, H. (09 February 2007). A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell, 128 (3), 589-600. doi:10.1016/j.cell.2006.12.036 https://hdl.handle.net/2268/12225

Herkenne, S., Bajou, K., Nguyen, N.-Q.-N., Martial, J., & Struman, I. (19 May 2012). Implication of the PAI-1/uPA/uPAR signalosome in the antiangiogenic action of 16K prolactin [Poster presentation]. GIGA-Cancer Day, Liège, Belgium.

Halkein, J., Tabruyn, S., Haghikia, A., Hoch, M., Nguyen, N.-Q.-N., Scherr, M., Castermans, K., Malvaux, L., Lambert, V., Sliwa, K., Noël, A., Martial, J., Hilfiker-Kleiner, D., & Struman, I. (19 May 2012). MicroRNA-146a, a downstream effector of 16K prolactin, is a therapeutic target and a specific biomarker for peripartum cardiomyopathy [Poster presentation]. GIGA-Cancer Day, Liège, Belgium.

Halkein, J., Tabruyn, S., Haghikia, A., Hoch, M., Nguyen, N.-Q.-N., Scherr, M., Castermans, K., Malvaux, L., Lambert, V., Sliwa, K., Noël, A., Martial, J., Hilfiker-Kleiner, D., & Struman, I. (April 2012). MicroRNA-146a is a causative factor and a specific biomarker for peripartum cardiomyopathy [Poster presentation]. Biomedica, Liège, Belgium.

Herkenne, S., Dalla Valle, A., Bajou, K., Nguyen, N.-Q.-N., Martial, J., & Struman, I. (April 2012). Implication of the PAI-1/uPA/uPAR complex in the antiangiogenic action of 16K prolactin [Poster presentation]. Biomedica, Liège, Belgium.

Struman, I., Halkein, J., Tabruyn, S., Haghiskia, A., Hoch, M., Nguyen, N.-Q.-N., Malvaux, L., sliwa, K., Noël, A., Martial, J., & Hilfiker-kleiner, D. (2012). MicroRNA-146a, a downstream effector of 16kDa prolactin, impairs the endothelium-cardiomyocyte cross-talk in peripartum cardiomyopathy. In FASEB meeting:the Growth Hormone/Prolactin Family in Biology and Disease.
Peer reviewed

Herkenne, S., Dalla Valle, A., Bajou, K., Nguyen, N.-Q.-N., Martial, J., & Struman, I. (2012). Implication of the PAI-1/uPA/uPAR complex in the antiangiogenic action of 16K hPRL [Poster presentation]. Keystone symposia on Angiogenesis: Advances in Basic Science and Therapeutic Applications, Snowbird, United States - Utah.

Nguyen, N.-Q.-N., Castermans, K., Berndt, S., Herkenne, S., Tabruyn, S., Blacher, S., Lion, M., Noël, A., Martial, J., & Struman, I. (07 November 2011). The Antiangiogenic 16K Prolactin Impairs Functional Tumor Neovascularization by Inhibiting Vessel Maturation. PLoS ONE, 6 (11), 27318-27318. doi:10.1371/journal.pone.0027318
Peer Reviewed verified by ORBi

Nguyen, N.-Q.-N., Castermans, K., Berndt, S., Herkenne, S., Tabruyn, S., Blacher, S., Lion, M., Noël, A., Martial, J., & Struman, I. (May 2011). The antiangiogenic 16K prolactin disturbs functional tumor neovascularization by affecting vessel maturation [Poster presentation]. 4th International Meeting on Angiogenesis, Amsterdam, Netherlands.

Herkenne, S., Bajou, K., D'Amico, S., Nguyen, N.-Q.-N., Martial, J., & Struman, I. (2011). Implication of the PAI-1/uPA/uPAR complex in the effects of the antiangiogenic factor 16K hPRL [Poster presentation]. Giga cancer day, Liège, Belgium.

Nguyen, N.-Q.-N. (2011). The antiangiogenic 16K prolactin impairs functional tumor neovascularization by affecting vessel maturation [Paper presentation]. Giga cancer, Liège, Belgium.

Kinet, V., Nguyen, N.-Q.-N., Sabatel, C., Bajou, K., Blacher, S., Noël, A., Martial, J., & Struman, I. (2009). Evaluation of the antitumor activity of 16K prolactin [Poster presentation]. Keystone symposia: angiogenesis and lymphangiogenesis in cancer, Big Sky, United States - Montana.

Nguyen, N.-Q.-N., Lion, M., Blacher, S., Camby, S., Castermans, K., Noël, A., Martial, J., & Struman, I. (2009). The antiangiogenic factor 16K hPRL affects tumor vessel maturation [Poster presentation]. Giga cancer day, Liège, Belgium.

Nguyen, N.-Q.-N., Camby, S., Lion, M., Blacher, S., Noël, A., Martial, J., & Struman, I. (2009). Evaluation of the ability of 16K hPRL to affect tumor vessel maturation [Poster presentation]. Biomedica, liège, Belgium.

Nguyen, N.-Q.-N. (2009). Evaluation of the ability of 16K hPRL to affect tumor vessel maturation [Paper presentation]. Giga cancer, Liège, Belgium.

Castermans, K., Nguyen, N.-Q.-N., Lecomte, J., Noël, A., Martial, J., & Struman, I. (2009). The contribution of vasculogenesis to tumor neovascularization after angiostatic treatment [Poster presentation]. Giga cancer day, liège, Belgium.

Halkein, J., Malvaux, L., Nguyen, N.-Q.-N., Martial, J., & Struman, I. (2009). Involvement of microRNAs in the regulation of angiogenesis by the antiangiogenic factor 16K [Poster presentation]. Biomedica, Liège, Belgium.

Halkein, J., Malvaux, L., Nguyen, N.-Q.-N., Martial, J., & Struman, I. (2009). Regulation of microRNAs expression by the antiangiogenic factor 16K hPRL [Poster presentation]. Giga cancer day, Liège, Belgium.

Kinet, V., Nguyen, N.-Q.-N., Sabatel, C., Blacher, S., Noël, A., Martial, J., & Struman, I. (2009). Antiangiogenic liposomal gene therapy with 16K human prolactin efficiently reduces tumor growth. Cancer Letters, 284 (2), 222-228. doi:10.1016/j.canlet.2009.04.030
Peer Reviewed verified by ORBi

Nguyen, N.-Q.-N., Camby, S., Blacher, S., Noël, A., Martial, J., & Struman, I. (2009). Study of the effect of the antiangiogenic factor 16K hPRL in tumor vessel maturation [Poster presentation]. Keystone symposia: angiogenesis and lymphangiogenesis in cancer, Bozeman, United States - Montana.

Martial, J., Struman, I., Nguyen, N.-Q.-N., Brasseur, R., & Lins, L. (14 February 2008). Antiangiogenic peptides.

Nguyen, N.-Q.-N., Cornet, A., Blacher, S., Tabruyn, S., Foidart, J.-M., Noël, A., Martial, J., & Struman, I. (December 2007). Inhibition of tumor growth and metastasis establishment by adenovirus-mediated gene transfer delivery of the antiangiogenic factor 16K hPRL. Molecular Therapy, 15 (12), 2094-2100. doi:10.1038/sj.mt.6300294
Peer Reviewed verified by ORBi

Martial, J., Struman, I., Nguyen, N.-Q.-N., Brasseur, R., & Lins, L. (02 May 2007). Antiangiogenic peptides.

Hilfiker-Kleiner, D., Kaminski, K., Podewski, E., Bonda, T., Schaefer, A., Sliwa, K., Forster, O., Quint, A., Landmesser, U., Doerries, C., Luchtefeld, M., Poli, V., Schneider, M. D., Balligand, J. L., Desjardins, F., Ansari, A., Struman, I., Nguyen, N.-Q.-N., Zschemisch, N. H., ... Drexler, H. (09 February 2007). A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell, 128 (3), 589-600. doi:10.1016/j.cell.2006.12.036
Peer Reviewed verified by ORBi

Nguyen, N.-Q.-N., Cornet, A., Blacher, S., Tabruyn, S., Foidart, J.-M., Noël, A., Martial, J., & Struman, I. (2007). Inhibition of tumor growth and metastasis establishment by adenovirus-mediated gene transfer delivery of the antiangiogenic factor 16K prolactin [Poster presentation]. Gordon research on angiogenesis, Newport, United States - Rhode Island.

Nguyen, N.-Q.-N., Cornet, A., Blacher, S., Tabruyn, S., FOIDART, J.-M., Noël, A., Martial, J., & Struman, I. (2007). Inhibition of tumor growth and metastasis by adenovirus-mediated gene transfer delivery of the antiangiogenic factor 16K prolactin [Poster presentation]. Keystone symposia: Host cell response to cancer, Bozeman, United States - Montana.

Tabruyn, S., Sabatel, C., Nguyen, N.-Q.-N., Verhaeghe, Castermans, K., Malvaux, L., Griffioen, A. W., Martial, J., & Struman, I. (2007). The angiostatic 16K human prolactin overcomes endothelial cell anergy and promotes leukocyte infiltration via nuclear factor-kappaB activation. Molecular Endocrinology, 21 (6), 1422-9. doi:10.1210/me.2007-0021
Peer Reviewed verified by ORBi

Kinet, V., Nguyen, N.-Q.-N., Cornet, A., Martial, J., & Struman, I. (2007). Evaluation of the antitumor activity of 16K prolactin [Poster presentation]. Keystone symposia:Host cell response to cancer, Keystone, United States - Colorado.

Nguyen, N.-Q.-N. (2006). Study of the effect of the antiangiogenic factor 16K hPRL on tumor growth and metastasis and identification of new antiangiogenic peptides [Doctoral thesis, Université de Liège]. ORBi-University of Liège. https://orbi.uliege.be/handle/2268/314773

Cornet, A., Nguyen, N.-Q.-N., Lion, M., Tabruyn, S., Sabatel, C., Kinet, V., Noël, A., Beckers, M.-C., Struman, I., & Martial, J. (May 2006). Molecular profiling of 16K PRL treated tumours by an antibody-array approach [Poster presentation]. Bioforum, Liège, Belgium.

Nguyen, N.-Q.-N., Tabruyn, S., Lins, L., Lion, M., Cornet, A., Rentier-Delrue, F., Brasseur, R., Martial, J., & Struman, I. (2006). Tilted peptides of PRL/GH family and their potential role in angiogenesis [Poster presentation]. Bioforum, Liège, Belgium.

Nguyen, N.-Q.-N., Tabruyn, S., Lins, L., Lion, M., Cornet, A., Lair, F., Rentier-Delrue, F., Brasseur, R., Martial, J., & Struman, I. (2006). Prolactin/growth hormone-derived antiangiogenic peptides highlight a potential role of tilted peptides in angiogenesis. Proceedings of the National Academy of Sciences of the United States of America, 103 (39), 14319-14324. doi:10.1073/pnas.0606638103
Peer Reviewed verified by ORBi

Nguyen, N.-Q.-N., Cornet, A., Tabruyn, S., Rentier-Delrue, F., Noël, A., Martial, J., & Struman, I. (2006). Evaluation of 16K Prolactin to prevent metastatic spread through inhibition of angiogenesis [Poster presentation]. Gordon Research Conference: Prolactin Family, Ventura, United States - California.

Nguyen, N.-Q.-N., Cornet, A., Tabruyn, S., Rentier-Delrue, F., Noël, A., Martial, J., & Struman, I. (2006). Adenovirus-mediated gene transfer of 16K prolactin inhibits B16-F10 tumor growth and metastasis [Poster presentation]. Bioforum, Liège, Belgium.

Tabruyn, S., Nguyen, N.-Q.-N., Cornet, A., Martial, J., & Struman, I. (July 2005). The antiangiogenic factor, 16-kDa human prolactin, induces endothelial cell cycle arrest by acting at both the G(0)-G(1) and the G(2)-M phases. Molecular Endocrinology, 19 (7), 1932-1942. doi:10.1210/me.2004-0515
Peer Reviewed verified by ORBi

Pan, H., Nguyen, N.-Q.-N., Yoshida, H., Bentzien, F., Shaw, L. C., Rentier-Delrue, F., Martial, J., Weiner, R., Struman, I., & Grant, M. B. (July 2004). Molecular targeting of antiangiogenic factor 16K hPRL inhibits oxygen-induced retinopathy in mice. Investigative Ophthalmology and Visual Science, 45 (7), 2413-2419. doi:10.1167/iovs.03-1001
Peer Reviewed verified by ORBi

Tabruyn, S., Nguyen, N.-Q.-N., Rentier-Delrue, F., Martial, J., & Struman, I. (14 May 2004). Molecular mechanisms involved in apoptosis and cell cycle arrest induced by the antiangiogenic factor 16K hPRL [Poster presentation]. Faseb meeting 2005.

Nguyen, N.-Q.-N., Rentier-Delrue, F., Martial, J., & Struman, I. (2004). The 16 kDa N-terminal fragment of the human prolactin. Design and production of minimal peptides retaining antiangiogenic and antitumoral properties [Poster presentation]. Association belge pour l’étude du cancer, Liège, Belgium.

Nguyen, N.-Q.-N., Rentier-Delrue, F., Martial, J., & Struman, I. (2003). Design and production of minimal peptides that retain antiangiogenic and antitumoral properties of the 16K N-terminal fragment of the human prolactin [Poster presentation]. Euroconférences: Angiogenesis 2, Paris, France.

Contact ORBi